Title:Antibody Development to HCV Alternate Reading Frame Protein in Liver Transplant Candidate and its Computational Analysis
VOLUME: 17 ISSUE: 2
Author(s):Zahra Musavi, Tayebeh Hashempour*, Javad Moayedi, Behzad Dehghani, Farzaneh Ghassabi, Mehrdad Hallaji, Seyed Younes Hosseini, Ramin Yaghoubi , Siavash Gholami, Mohamad Ali Dehyadegari and Shahin Merat
Affiliation:Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Shiraz Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Shiraz Organ Transplant Unit, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran
Keywords:HCV, ARFP, LTC, liver transplant candidate patients, bioinformatics, chronic liver disease.
Abstract:
Background: HCV Alternate Reading Frame Protein (ARFP) is a frameshift product of
HCV-core encoding. Here, we characterized specific anti-ARFP antibodies in Liver Transplant Candidate
(LTC) and chronic HCV-infected patients.
Methods: The ARFP gene was cloned and the recombinant protein was purified using Nickel chromatography
and confirmed by western blotting. ELISA was developed using recombinant core-1a, core-
1b, ARFP-1a protein, and 99-residue synthetic ARFP 1b peptide. By several Bioinformatics tools,
general properties, immunogenic epitopes, and structures of these proteins were obtained.
Results: The seroprevalence of anti-core and anti-ARFP antibodies was 100% in LTC patients, but only
75.2% and 94.3% of chronic patients had evidence of anti-ARFP and anti-core antibodies, respectively.
In-silico results demonstrated physicochemical features, antigen properties and potential interactors
that could describe progression toward advanced liver disease.
Conclusion: As the first report, the prevalence of anti-ARFP antibodies in LTC patients is of the order
of 100% and titer of anti-ARFP antibody was significantly higher in LTC patients compared to chronic
individuals, suggesting the possible role of ARFP in the progression toward advanced liver disease. In
addition, docking analysis determined several interactor proteins such as prefoldin 2, cathepsin B, vitronectin,
and angiotensinogen that have an important role in progression to chronic infection and liver
disease development.
